Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1770 - A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy

Presenters

Maria Gonzalez-Cao

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

M. Gonzalez-Cao1, J. Martinez-Picado2, M. Provencio Pulla3, B. Clotet2, O. Juan4, J. Dalmau2, T. Moran5, A. Mayerhans6, J. De Castro7, J. Blanco2, R. Blanco8, R. Bernabe Caro9, N. Karachaliou10, J. Garcia-Corbacho11, M.A. Molina1, C. Brander2, R. Rosell12

Author affiliations

  • 1 Oncology Department, Quirón Dexeus University Hospital, 08028 - Barcelona/ES
  • 2 Aids Research Institute, Hospital Universitari Germans Trias i Pujol, badalona/ES
  • 3 Medical Oncology, Hospital Puerta de Hierro Majadahonda, 28221 - Majadahonda/ES
  • 4 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 5 Medical Oncology, Hospital Universitari Germans Trias i Pujol, badalona/ES
  • 6 Icrea, Universidad Pompeu Fabra, Barcelona/ES
  • 7 Medical Oncology, Hospital la Paz, Madrid/ES
  • 8 Medical Oncology, Mutua Terrassa, Barcelona/ES
  • 9 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 10 Medical Oncology, Hospital Sagrado Corazon, 8029 - Barcelona/ES
  • 11 Oncology Department, Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES
  • 12 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
More

Resources

Abstract 1770

Background

Although acquired immunodeficiency syndrome-related mortality is decreasing with the introduction of effective antiretroviral therapy, it has been reported a significant increase in the proportion of non-acquired immunodeficiency syndrome defining malignancies in HIV infected patients, often associated with premature immunosenescence and exhaustion. It has been shown in murine models and humans that programmed cell death ligand 1 (PD-L1) and its receptor, programmed cell death 1 (PD-1) play an active and reversible role mediating T-cell exhaustion both in cancer and in chronic infections. Binding PD-1 to its ligand PD-L1negatively regulates T-cell response, leading to an exhausted phenotype on CD8+ T cells. Therefore, there is a potential of immunotherapeutic intervention targeting PD-1/PD-L1 in order to enhance anti tumoral immune responses as well as to facilitate viral eradication. Durvalumab (MEDI4736) is a human monoclonal antibody (MAb) of the immunoglobulin G1 kappa (IgG1κ) subclass that inhibits binding of programmed cell death ligand 1 (PD-L1) to programmed cell death 1 (PD-1; CD279) and CD80 (B7-1). Durvalumab has demonstrated in cancer patients a favorable safety profile with encouraging antitumor activity, but there are no data about tolerance or anti retroviral activity in HIV patients.

Trial design

This is an ongoing multicenter, open-label, phase 2 study (EUDRACT: 2016-004524-38) whose primary objective is to assess the feasibility of durvalumab at the recommended dose of 1500 mg every 4 weeks in HIV-infected patients with solid tumors for which no additional oncologic standard treatment is available. As secondary objectives the response rate (RECIST 1.1 and irRECIST), duration of response, PFS and OS will be measured. Exploratory objectives include the assessment of antiviral activity by measuring the changes in the HIV viral reservoir, the residual viral replication and the composition and function of circulating T lymphocytes and the study of molecular predictive factors of antitumoral activity on pretreatment tumor samples.

Clinical trial identification

EUDRACT: 2016-004524-38

Legal entity responsible for the study

Spanish Lung Cancer Group

Funding

AZ Spain

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.